PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. - Wikidata - awgldk - TriplyDB

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.

http://www.wikidata.org/entity/Q37077437

about

Current management and perspectives for HCV recurrence after liver transplantation Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation Management of hepatitis c genotype 4 in the liver transplant setting Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management Surgical approach for hepatitis C virus-related hepatocellular carcinoma Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation Hepatitis C: New challenges in liver transplantation Challenges of recurrent hepatitis C in the liver transplant patient Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.Recurrent hepatitis C after liver transplant Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis.Future treatment of patients with HCV cirrhosis.Management of recurrent hepatitis C virus after liver transplantation.Griffithsin has antiviral activity against hepatitis C virus A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study Living-donor liver transplantation and hepatitis C Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.New perspectives for preventing hepatitis C virus liver graft infection.Hepatitis C virus treatment pre- and post-liver transplantation.Telaprevir/boceprevir era: from bench to bed and back.Hepatitis B and C in liver transplantation: new strategies to combat the enemies.Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients.Hepatitis C recurrence: the Achilles heel of liver transplantation.Management of HCV transplant patients with triple therapy.Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals.Management of post transplant hepatitis C in the direct antiviral agents era.Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances.Management of Post-Liver Transplant Recurrence of Hepatitis C.Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.

P2860

Q22299427-8AA8FDC5-542A-4C9C-9FD6-94F25CF7FD32 Q24202008-0B013112-1435-4BA4-8288-3B8727AE912A Q26749326-A331ED9A-90CD-469A-9490-7060C2057BB7 Q26781331-2B4AFD07-F6F4-4520-98A0-606FBD5D881D Q26781741-6AA1ABD8-8189-4B4B-AFF0-DF187AE78AD5 Q26781984-345D4487-3FE9-4E03-9E2D-3CBFA9F3709E Q26824046-DB5EDF2B-68A1-44C0-B9BB-BCC852E5A62A Q26864647-CAA45205-F354-4900-8559-9D12DBF62A75 Q26999368-9C878AF3-0864-4CF8-BAD3-FCC94DBAE7F4 Q27011871-52CF21DF-599C-42F4-96D3-F1DC02D109F4 Q28483065-4DB86F72-F2D7-417B-9978-6C30DFB6AB97 Q33423299-02241D99-3CE9-40FC-8052-FF0088755953 Q34067825-BB829554-8EDC-47FB-9C54-391641978F5B Q34093754-DA67876D-2549-45B9-B24C-2550E0F34ADB Q34119509-7834CF00-3411-4DB2-AB0C-24EAF77596D7 Q34243993-02E72250-8354-4E0B-B272-B50ED8CD3B11 Q34589655-AC1F8EA0-9E9E-44B2-8038-A9B92AEEE291 Q35363633-52D827DE-3B50-4890-A396-E8A8DF6C7664 Q35685409-95DB070F-FF08-43EC-8FBF-527DBA25B326 Q35790393-2D4E4560-5F51-41E0-B238-A3928F857BB4 Q35980958-1A63C8F2-9D5C-4637-BA24-424DB1EE7863 Q36241697-607DCFC0-7379-490F-836F-8CAC41BCCF95 Q36476188-1F4A120A-9AE7-4661-8ED6-C13B6B80888D Q36587253-B87CBB83-162B-4F92-B0C1-43B8386B795E Q36745425-A187B468-C2D1-428D-AB6E-35A83CD36880 Q37015805-75D3A92C-81C1-4ACE-B344-03F4A0DFF0C0 Q37972771-B621087F-DE88-4D41-89C8-09EA96B1CB93 Q38062524-147B85FB-F84F-4E30-A78D-ED57C2D03B72 Q38067343-ABD8BEDD-85AA-49A3-82D7-485E596E0BD6 Q38083754-B2DE8B65-9617-4535-A9F7-54FE5F077368 Q38174194-E001B3A7-5C9D-4D2A-B44B-519EF5B12FEA Q38174249-291613F4-8C12-461A-89B9-79C6F4280A0A Q38204468-61C3729B-C934-4610-8E57-61E5D58F6AF4 Q38265900-BCEF61F9-5E98-446A-AC07-9E96C357F854 Q38395275-95F74795-3C45-4B09-9912-E8062BF0C55F Q38584289-B2695726-0BB6-447E-A7D0-076909E3A6FD Q39017681-C6FF9B83-E69F-49A7-8326-867ABD274B76 Q39885523-DC8CA680-2278-4989-A58B-E6799F06D975 Q40271866-BEC8137A-3C3E-4B8C-8593-D2BF51E04740 Q41006072-7D76F66F-3D19-49A3-9811-8430D962BDCC

P2860

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.

http://www.wikidata.org/entity/Q37077437

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PHOENIX: A randomized controll ...... ntation for hepatitis C virus.

@en

PHOENIX: A randomized controll ...... ntation for hepatitis C virus.

@nl

type

label

PHOENIX: A randomized controll ...... ntation for hepatitis C virus.

@en

PHOENIX: A randomized controll ...... ntation for hepatitis C virus.

@nl

prefLabel

PHOENIX: A randomized controll ...... ntation for hepatitis C virus.

@en

PHOENIX: A randomized controll ...... ntation for hepatitis C virus.

@nl

P1433

Q37077437-ED9F2D12-C822-43EB-8002-F4D2AD44C1A5

P1476

Q37077437-C060100E-507D-47B9-8490-9E6F3DF505A6

P2093

Q37077437-11976FB6-7E8A-4B7C-9BA3-230858A958F0

Q37077437-1DE63853-4E6E-4AE8-BBBC-C8749307BFA1

Q37077437-26363438-603A-45C1-8C56-590D845CD05D

Q37077437-6DAEBBE3-0315-4202-83B6-A6A1CF9AA8C2

Q37077437-70274FDC-F9A4-4A9F-B3D7-1ECAABC8B61A

Q37077437-899252AD-AA45-4D80-B648-1514D5EE7359

Q37077437-F4BE1259-9BF5-4FEA-934E-260B17634CC6

Q37077437-FE5354CC-041F-4F75-90FF-06B1D90BCCEC

P2860

Q37077437-06932161-D37D-49C1-903C-F5BE085F7650

Q37077437-0AB9983A-7ED6-4FA2-9BA2-CFC2CAAE7F94

Q37077437-1623964A-23EF-414B-9A5E-30D545A28182

Q37077437-1CC1C291-29F3-4340-BAE8-B557339DDCDC

Q37077437-3076E49A-565C-484B-9E42-4FC94EDD0EC7

Q37077437-313EEDB1-DF34-4757-A648-62878A2EA0BF

Q37077437-3385F17B-8CFE-434C-BA3B-FF7B6AD93699

Q37077437-346D83E6-B4C2-4538-8689-6D5DCAF5FA37

Q37077437-3F86107E-E8AC-40C3-B891-EF030A5E5A22

Q37077437-551E25E0-4E7D-437F-9403-77CE488EB2DA

P304

Q37077437-EA436A49-F203-44E2-83AE-09341B2BBD42

P31

Q37077437-6457FB48-00EB-445A-8E40-E6B1F9BE796A

P356

Q37077437-C4C758F0-D30F-4B0D-B167-67E1249E1CD9

P433

Q37077437-32989815-D214-400E-9A06-AFFA8A6ABEB5

P478

Q37077437-826249A9-EE42-456A-A4E8-852B4B55369D

P577

Q37077437-D1CD9AEB-ACE3-4717-9293-DE3E17D57197

P5875

Q37077437-3AEC95C7-D782-43D4-8878-62D7D76C933A

P698

Q37077437-92065E37-5DEF-4550-953E-C22546F73BF0

P921

Q37077437-6DC08EDE-A02B-44E2-BD57-DA73CF7E19BA

P932

Q37077437-1E320BEE-528A-4A64-89E4-54B3A9E1B3A5

P356

P1433

Liver Transplantation

P1476

PHOENIX: A randomized controll ...... ntation for hepatitis C virus.

@en

P2093

Avinash Prabhakar

http://www.w3.org/2001/XMLSchema#string

David R Nelson

http://www.w3.org/2001/XMLSchema#string

Gregory T Everson

http://www.w3.org/2001/XMLSchema#string

Lichen L Teng

http://www.w3.org/2001/XMLSchema#string

Michael R Charlton

http://www.w3.org/2001/XMLSchema#string

Natalie Bzowej

http://www.w3.org/2001/XMLSchema#string

Norah A Terrault

http://www.w3.org/2001/XMLSchema#string

PHOENIX Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.

Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry.

Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.

Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation.

Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy.

Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis.

A practical guide to the management of HCV infection following liver transplantation.

P304

528-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/LT.22271

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51063824

http://www.w3.org/2001/XMLSchema#string

P698

21506241

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation

P932

3736350

http://www.w3.org/2001/XMLSchema#string